COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis

Kazuki Takasaki, Takumi Tsunenari, Kazuma Mori, Satsuki Aochi

SUMMARY
A 40-year-old man was admitted to our hospital for COVID-19. He had been treated for essential thrombocythemia (ET). He was diagnosed severe illness of COVID-19, oxygen therapy and dexamethasone were administered. There was a possibility of thromboembolic events in this case, apixaban for prophylaxis was added. With these treatments, the patient has made a good recovery, and he was discharged on hospital day 11. There is no standard strategy for prophylaxis of thrombosis in patients with ET, and apixaban could be a clinical benefit for these patients.

BACKGROUND
Since December 2019, SARS-CoV-2 has emerged in China, and spread worldwide rapidly, posing serious challenges to medical care system. COVID-19 is characterised by the occurrence of venous thromboembolism (VTE) and/or arterial thrombosis, which could lead to severe morbidity and mortality. Moreover, patients with myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera and myelofibrosis, are reported to be prone to develop thrombotic complications. There are few reports of COVID-19 cases complicated with MPNs, and further researches are required to establish the treatment strategy in patients with MPNs. Our case describes a patient, who had been treated for ET, treated with supplemental oxygen, dexamethasone and apixaban for prophylaxis of thrombosis. This article could highlight the clinical benefit of prophylaxis and antithrombotic therapy in cases with ET.

CASE PRESENTATION
The patient is a 40-year-old man with a medical history significant for ET, who had been treated with hydroxycarbamide and aspirin. International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPET-thrombosis) score was intermediate, and International Working Group-Myeloproliferative neoplasms Research and Treatment (IWG-MRT) score was 0 (low risk). He complained fever, dry cough, malaise and arthralgia. A nasopharyngeal swab for SARS-CoV-2 test was done, being positive. On the ninth day of isolation, his symptoms did not improve, and he was admitted to our hospital.

On admission, he was alert. Temperature was 37.5°C, pulse 83 bpm, blood pressure 123/69 mm Hg, respiratory rate 23 times/min and pulse oximeter 90% saturation without supplemental oxygen.
COVID-19 in general wards, but the incidence of thrombosis is lower in Japan (1.86% of all hospitalised patients with COVID-19). Of the thromboses, deep vein thrombosis and pulmonary thromboembolism are the most frequent, but symptomatic cerebral infarction is also frequent entity.

In addition to high incidence of thrombosis in patients with COVID-19, patients with MPNs are thought to be vulnerable to these events. Patients with MPNs suffer from a 2–4-fold higher incidence of arterial and venous thrombosis than the general population. Moreover, there is a study reporting that ET is associated with the risk of VTE among patients with MPNs, and that the association between ET and thrombosis was regardless of inflammation indicators and the severity of COVID-19. To detect thromboses early, d-dimer level is reported to be a clinical biomarker predicting thrombosis, and in patients with ET complicated with venous thrombosis, d-dimer values were reported to be significantly higher than the ones without thrombosis. The platelet count is reported to be significantly lower during the acute phase of infection than the values collected in the latest follow-up, and which might indicate a platelet consumption due to low grade disseminated coagulation by systemic endothelial vascular cell damage, leading to arterial or venous thrombosis. Our case showed normal value of d-dimer but lower platelet count than the last follow-up, and the case was diagnosed severe illness of COVID-19, which could not deny the possibility of thrombosis.

However, there is no standard prophylaxis and antithrombotic therapy in patients with ET complicated with COVID-19, because the prevalence of MPNs is low and there are few reports. There is only one retrospective study of patients with MPNs complicated with COVID-19, and most cases received low molecular weight heparin (LMWH) as antithrombotic prophylaxis. But there is a problem of bleeding in the treatment of heparin. 4.3% of patients receiving LMWH showed major bleeding. There is another report that showed clinical benefit of apixaban for antithrombotic prophylaxis in patients with COVID-19, resulting in decreased mortality without increasing the risk of bleeding. In our case, apixaban was administered for antithrombotic prophylaxis, and there were no symptoms suggesting thrombosis, and there was no bleeding. Therefore, we speculate that apixaban could be useful and safe antithrombotic prophylaxis for patients with ET complicated with COVID-19.

The number of reports showing the association of COVID-19 and ET is very small, so further investigations are required to establish the safe and effective management strategy.

Contributors KT contributed to conception and design. KT, KM contributed to acquisition of data. KT, TT contributed to analysis and interpretation of data. KT, SA contributed to drafting and revision of the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Consent obtained directly from patient(s)

Provenance and peer review Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

ORCID iD Kazuki Takasaki http://orcid.org/0000-0001-6671-1858

REFERENCES
1 Machhi J, Herskovitz J, Senan AM, et al. The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. J Neuroimmune Pharmacol 2020;15:359–86.
2 Nopp S, Moik F, Illma B, et al. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Res Pract Thromb Haemost 2020;4:1178–91.
3 Barbui T, De Stefano V, Alvarez-Larran A, et al. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood Cancer J 2021;11:21.
4 National Institutes of Health. COVID-19 treatment guidelines, 2021. Available: https://www.covid19treatmentguidelines.nih.gov/about-the-guideline/ [Accessed 1 Sep 2021].
5 Horiuchi H, Morishita E, Urano T, et al. COVID-19-Related thrombosis in Japan: final report of a questionnaire-based survey in 2020. J Intern Med 2021;28:406–16.
6 Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood 2013;122:2176–84.
7 Hultcrantz M, Bjorkholm M, Dickman PW, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med 2018;168:317–25.
8 Arifin M, Danic G, Gautier G, et al. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. Thromb Res 2020;50:211–6.
9 Billett HH, Reyes-Gil M, Symanski J, et al. Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality. Thromb Haemost 2020;120:1691–9.

Learning points

► Essential thrombocythemia (ET) could cause thrombosis complicated with COVID-19. The clinicians should consider the possibility of thromboembolic events.
► There are no standard strategies for thromboembolic events associated with COVID-19, especially in patients with ET. Apixaban could be of clinical benefit in prophylaxis for thrombosis in patients with ET.